Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized Phase 3 study of peginterferon beta-1a versus interferon beta-1a in relapsing remitting multiple sclerosis
2018-003008-38Phase 3Active
- Sponsor
- Biogen
- Start
- Mar 2019
- Modality
- Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon beta in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoint: Annualized relapse rate at Week 96 (Part 1 primary endpoint). Started Mar 2019; status: active.
02
Drugs
interferon beta
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-003008-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003008-38.